Placebo Controlled Study of Sublingual Salvinorin A
Not Applicable
Completed
- Conditions
- Pharmaceutical Preparations
- Interventions
- Drug: Placebo
- Registration Number
- NCT01149824
- Brief Summary
In this study, our aim is to determine an active but tolerable sublingual dose (range 100 to 4000 µg) of Salvinorin A (SA) in experienced subjects. This study is an ascending-dose, placebo-controlled, single-site design in 8 Salvia-experienced subjects. Subjects will receive SA doses from 0-4000 µg. Doses will be separated by at least one day. The first two doses (0 and 100µg) will be double-blinded while the last four (250, 500, 1000, 2000 and 4000µg) will be single-blind.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 8
Inclusion Criteria
- Male or female, aged 21-45
- Experienced with hallucinogenic amounts of SA
- Good physical and mental health
- Able to give adequate informed consent
Exclusion Criteria
- Any medical or psychiatric condition which, in the investigators' opinion, would preclude safe or consistent participation
- Significant acute or chronic medical disease
- Female who is pregnant, lactating, or plans to become pregnant during the study period and within one month after study drug administration
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Dose Escalating Salvinorin A - Dose Escalating Placebo -
- Primary Outcome Measures
Name Time Method To determine an active but tolerable sublingual dose (range 100 to 4000 µg) of Salvinorin A (SA) in experienced subjects. 2 hours
- Secondary Outcome Measures
Name Time Method